Hugh D C Smyth (Tania F Bahamondez-Canas)

Years Active: 2018-2021
Publications (10 Years): 5

Universidad de Valparaíso

University of Texas at Austin (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universidad de Valparaíso Dec 15 2019

Chile

Associate Professor :: College of Pharmacy

Universidad de Valparaiso

Chile

Postdoctoral research fellow and Lecturer :: Collegel of Pharmacy

Universidad Tecnica Federico Santa Maria

Chile

Project Assistant :: Centro de Biotecnologia Dr. Daniel Alkalay Lowitt

University of Texas at Austin

United States

Graduated Research Assistant :: Molecular Pharmaceutics and Drug Delivery

University of Texas at Austin

United States

Teaching Assistant :: Molecular Pharmaceutics and Drug Delivery

Education History

University of Texas at Austin Aug 20 2013 - May 19 2018

United States

PHD :: Molecular Pharmaceutics and Drug Delivery

Publications

Jonattan Gallegos-Catalán, Zachary Warnken, Hugh D C Smyth, Daniel Moraga-Espinoza
Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process. Pharmaceutics 13 (7) (2021)
Ashlee D Brunaugh, Tian Wu, Sekhar R Kanapuram, Hugh D C Smyth
Effect of Particle Formation Process on Characteristics and Aerosol Performance of Respirable Protein Powders. Molecular pharmaceutics 16 (10) (2019)
Hairui Zhang, Hugh D C Smyth, Yajie Zhang, Jasmim Leal, Hugh D C Smyth
PEGylated Chitosan for Nonviral Aerosol and Mucosal Delivery of the CRISPR/Cas9 System in Vitro. Molecular pharmaceutics 15 (11) (2018)
Zachary N Warnken, Hugh D C Smyth, Daniel A Davis, Steve Weitman, John G Kuhn, Robert O Williams
Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts. Molecular pharmaceutics 15 (4) (2018)
Hugh D C Smyth, Hairui Zhang, Frederic Tewes, Jasmim Leal, Hugh D C Smyth
PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro. Molecular pharmaceutics 15 (4) (2018)

Hugh D C Smyth.css-eqlu8i{font-size:small;padding-left:4px;} (Tania F Bahamondez-Canas)